1. Home
  2. PEB vs GENB Comparison

PEB vs GENB Comparison

Compare PEB & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pebblebrook Hotel Trust of Beneficial Interest

PEB

Pebblebrook Hotel Trust of Beneficial Interest

HOLD

Current Price

$19.51

Market Cap

1.7B

Sector

Real Estate

ML Signal

HOLD

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$14.69

Market Cap

1.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
PEB
GENB
Founded
2009
2018
Country
United States
United States
Employees
52
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PEB
GENB
Price
$19.51
$14.69
Analyst Decision
Hold
Strong Buy
Analyst Count
11
6
Target Price
$13.30
$23.20
AVG Volume (30 Days)
2.2M
540.9K
Earning Date
04-28-2026
05-11-2026
Dividend Yield
0.28%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.25
$16.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.30
$11.00
52 Week High
$19.93
$18.18

Technical Indicators

Market Signals
Indicator
PEB
GENB
Relative Strength Index (RSI) 58.43 52.88
Support Level $18.35 $11.82
Resistance Level $19.76 $14.82
Average True Range (ATR) 0.60 0.75
MACD -0.07 0.05
Stochastic Oscillator 65.82 98.09

Price Performance

Historical Comparison
PEB
GENB

About PEB Pebblebrook Hotel Trust of Beneficial Interest

Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,052 rooms across 44 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: